Copyright Reports & Markets. All rights reserved.

Global Fluorine-18 Radiopharmaceuticals Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Fluorine-18 Radiopharmaceuticals Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Nucleophilic Labeling
    • 1.3.3 Electrophilic Labeling
  • 1.4 Market Analysis by Functional
    • 1.4.1 Overview: Global Fluorine-18 Radiopharmaceuticals Consumption Value by Functional: 2021 Versus 2025 Versus 2032
    • 1.4.2 Metabolic Tracers
    • 1.4.3 Receptor-Binding Tracers
    • 1.4.4 Amino Acid Transporters
    • 1.4.5 Others
  • 1.5 Market Analysis by Specific Activity
    • 1.5.1 Overview: Global Fluorine-18 Radiopharmaceuticals Consumption Value by Specific Activity: 2021 Versus 2025 Versus 2032
    • 1.5.2 High Specific Activity
    • 1.5.3 Low Specific Activity
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Fluorine-18 Radiopharmaceuticals Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Medical Imaging
    • 1.6.3 Scientific Research
  • 1.7 Global Fluorine-18 Radiopharmaceuticals Market Size & Forecast
    • 1.7.1 Global Fluorine-18 Radiopharmaceuticals Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Fluorine-18 Radiopharmaceuticals Sales Quantity (2021-2032)
    • 1.7.3 Global Fluorine-18 Radiopharmaceuticals Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 ANSTO
    • 2.1.1 ANSTO Details
    • 2.1.2 ANSTO Major Business
    • 2.1.3 ANSTO Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.1.4 ANSTO Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 ANSTO Recent Developments/Updates
  • 2.2 Rosatom
    • 2.2.1 Rosatom Details
    • 2.2.2 Rosatom Major Business
    • 2.2.3 Rosatom Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.2.4 Rosatom Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Rosatom Recent Developments/Updates
  • 2.3 Eckert & Ziegler
    • 2.3.1 Eckert & Ziegler Details
    • 2.3.2 Eckert & Ziegler Major Business
    • 2.3.3 Eckert & Ziegler Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.3.4 Eckert & Ziegler Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Eckert & Ziegler Recent Developments/Updates
  • 2.4 CNNC
    • 2.4.1 CNNC Details
    • 2.4.2 CNNC Major Business
    • 2.4.3 CNNC Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.4.4 CNNC Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 CNNC Recent Developments/Updates
  • 2.5 Curium Pharma
    • 2.5.1 Curium Pharma Details
    • 2.5.2 Curium Pharma Major Business
    • 2.5.3 Curium Pharma Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.5.4 Curium Pharma Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Curium Pharma Recent Developments/Updates
  • 2.6 GE HealthCare
    • 2.6.1 GE HealthCare Details
    • 2.6.2 GE HealthCare Major Business
    • 2.6.3 GE HealthCare Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.6.4 GE HealthCare Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 GE HealthCare Recent Developments/Updates
  • 2.7 Jubilant Radiopharma
    • 2.7.1 Jubilant Radiopharma Details
    • 2.7.2 Jubilant Radiopharma Major Business
    • 2.7.3 Jubilant Radiopharma Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.7.4 Jubilant Radiopharma Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Jubilant Radiopharma Recent Developments/Updates
  • 2.8 Cardinal Health
    • 2.8.1 Cardinal Health Details
    • 2.8.2 Cardinal Health Major Business
    • 2.8.3 Cardinal Health Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.8.4 Cardinal Health Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Cardinal Health Recent Developments/Updates
  • 2.9 IBA
    • 2.9.1 IBA Details
    • 2.9.2 IBA Major Business
    • 2.9.3 IBA Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.9.4 IBA Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 IBA Recent Developments/Updates
  • 2.10 Sumitomo Heavy Industries
    • 2.10.1 Sumitomo Heavy Industries Details
    • 2.10.2 Sumitomo Heavy Industries Major Business
    • 2.10.3 Sumitomo Heavy Industries Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.10.4 Sumitomo Heavy Industries Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Sumitomo Heavy Industries Recent Developments/Updates
  • 2.11 Sinotau
    • 2.11.1 Sinotau Details
    • 2.11.2 Sinotau Major Business
    • 2.11.3 Sinotau Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.11.4 Sinotau Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Sinotau Recent Developments/Updates
  • 2.12 Nueclear Healthcare
    • 2.12.1 Nueclear Healthcare Details
    • 2.12.2 Nueclear Healthcare Major Business
    • 2.12.3 Nueclear Healthcare Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.12.4 Nueclear Healthcare Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Nueclear Healthcare Recent Developments/Updates
  • 2.13 DC Pharma
    • 2.13.1 DC Pharma Details
    • 2.13.2 DC Pharma Major Business
    • 2.13.3 DC Pharma Fluorine-18 Radiopharmaceuticals Product and Services
    • 2.13.4 DC Pharma Fluorine-18 Radiopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 DC Pharma Recent Developments/Updates

3 Competitive Environment: Fluorine-18 Radiopharmaceuticals by Manufacturer

  • 3.1 Global Fluorine-18 Radiopharmaceuticals Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Fluorine-18 Radiopharmaceuticals Revenue by Manufacturer (2021-2026)
  • 3.3 Global Fluorine-18 Radiopharmaceuticals Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Fluorine-18 Radiopharmaceuticals by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Fluorine-18 Radiopharmaceuticals Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Fluorine-18 Radiopharmaceuticals Manufacturer Market Share in 2025
  • 3.5 Fluorine-18 Radiopharmaceuticals Market: Overall Company Footprint Analysis
    • 3.5.1 Fluorine-18 Radiopharmaceuticals Market: Region Footprint
    • 3.5.2 Fluorine-18 Radiopharmaceuticals Market: Company Product Type Footprint
    • 3.5.3 Fluorine-18 Radiopharmaceuticals Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Fluorine-18 Radiopharmaceuticals Market Size by Region
    • 4.1.1 Global Fluorine-18 Radiopharmaceuticals Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Fluorine-18 Radiopharmaceuticals Consumption Value by Region (2021-2032)
    • 4.1.3 Global Fluorine-18 Radiopharmaceuticals Average Price by Region (2021-2032)
  • 4.2 North America Fluorine-18 Radiopharmaceuticals Consumption Value (2021-2032)
  • 4.3 Europe Fluorine-18 Radiopharmaceuticals Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Fluorine-18 Radiopharmaceuticals Consumption Value (2021-2032)
  • 4.5 South America Fluorine-18 Radiopharmaceuticals Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Fluorine-18 Radiopharmaceuticals Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Fluorine-18 Radiopharmaceuticals Sales Quantity by Type (2021-2032)
  • 5.2 Global Fluorine-18 Radiopharmaceuticals Consumption Value by Type (2021-2032)
  • 5.3 Global Fluorine-18 Radiopharmaceuticals Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Fluorine-18 Radiopharmaceuticals Sales Quantity by Application (2021-2032)
  • 6.2 Global Fluorine-18 Radiopharmaceuticals Consumption Value by Application (2021-2032)
  • 6.3 Global Fluorine-18 Radiopharmaceuticals Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Fluorine-18 Radiopharmaceuticals Sales Quantity by Type (2021-2032)
  • 7.2 North America Fluorine-18 Radiopharmaceuticals Sales Quantity by Application (2021-2032)
  • 7.3 North America Fluorine-18 Radiopharmaceuticals Market Size by Country
    • 7.3.1 North America Fluorine-18 Radiopharmaceuticals Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Fluorine-18 Radiopharmaceuticals Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Fluorine-18 Radiopharmaceuticals Sales Quantity by Type (2021-2032)
  • 8.2 Europe Fluorine-18 Radiopharmaceuticals Sales Quantity by Application (2021-2032)
  • 8.3 Europe Fluorine-18 Radiopharmaceuticals Market Size by Country
    • 8.3.1 Europe Fluorine-18 Radiopharmaceuticals Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Fluorine-18 Radiopharmaceuticals Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Fluorine-18 Radiopharmaceuticals Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Fluorine-18 Radiopharmaceuticals Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Fluorine-18 Radiopharmaceuticals Market Size by Region
    • 9.3.1 Asia-Pacific Fluorine-18 Radiopharmaceuticals Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Fluorine-18 Radiopharmaceuticals Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Fluorine-18 Radiopharmaceuticals Sales Quantity by Type (2021-2032)
  • 10.2 South America Fluorine-18 Radiopharmaceuticals Sales Quantity by Application (2021-2032)
  • 10.3 South America Fluorine-18 Radiopharmaceuticals Market Size by Country
    • 10.3.1 South America Fluorine-18 Radiopharmaceuticals Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Fluorine-18 Radiopharmaceuticals Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Fluorine-18 Radiopharmaceuticals Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Fluorine-18 Radiopharmaceuticals Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Fluorine-18 Radiopharmaceuticals Market Size by Country
    • 11.3.1 Middle East & Africa Fluorine-18 Radiopharmaceuticals Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Fluorine-18 Radiopharmaceuticals Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Fluorine-18 Radiopharmaceuticals Market Drivers
  • 12.2 Fluorine-18 Radiopharmaceuticals Market Restraints
  • 12.3 Fluorine-18 Radiopharmaceuticals Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Fluorine-18 Radiopharmaceuticals and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Fluorine-18 Radiopharmaceuticals
  • 13.3 Fluorine-18 Radiopharmaceuticals Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Fluorine-18 Radiopharmaceuticals Typical Distributors
  • 14.3 Fluorine-18 Radiopharmaceuticals Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Fluorine-18 Radiopharmaceuticals market size was valued at US$ 206 million in 2025 and is forecast to a readjusted size of US$ 322 million by 2032 with a CAGR of 6.5% during review period.
    Fluorine-18 radiopharmaceuticals are specialized diagnostic agents utilized primarily in Positron Emission Tomography (PET) imaging. These compounds are synthesized by labeling biologically active molecules—such as glucose analogs, amino acids, or receptor-specific ligands—with the radioisotope Fluorine-18 . Due to its physical properties, including a positron-emitting decay mode and an optimal half-life of approximately 109.8 minutes, F18 is considered the gold standard for clinical molecular imaging. These radiopharmaceuticals enable the non-invasive visualization and quantification of metabolic, physiological, and pathological processes at the cellular level, playing a critical role in the precise diagnosis, staging, and monitoring of oncological, neurological, and cardiovascular diseases.
    In 2025, global Fluorine-18 radiopharmaceuticals production reached approximately 2 million GBq, and average price was 100 USD/GBq，with gross margin 65%
    The global Fluorine-18 market is experiencing steady expansion, driven primarily by the rising prevalence of chronic diseases such as cancer, Alzheimer’s, and cardiovascular disorders. As the gold standard radionuclide for Positron Emission Tomography (PET) imaging, Fluorine-18 benefits from its 110-minute half-life, which allows for efficient centralized production and distribution. Market growth is further propelled by the adoption of precision medicine, the expansion of cyclotron infrastructure, and the continuous development of novel radiotracers beyond traditional FDG. While North America remains the dominant region due to its advanced healthcare infrastructure and high utilization of PET/CT systems, the Asia-Pacific region is emerging as the fastest-growing market, fueled by significant investments in nuclear medicine and increasing healthcare accessibility. Future market trends emphasize the integration of AI in diagnostic imaging, the rise of "theranostics," and a strategic shift toward localized, hospital-adjacent cyclotron facilities to optimize supply chain efficiency.
    Report Scope
    This report is a detailed and comprehensive analysis for global Fluorine-18 Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Fluorine-18 Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (GBq), and average selling prices (US$/GBq), 2021-2032
    Global Fluorine-18 Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (GBq), and average selling prices (US$/GBq), 2021-2032
    Global Fluorine-18 Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (GBq), and average selling prices (US$/GBq), 2021-2032
    Global Fluorine-18 Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (GBq), and ASP (US$/GBq), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Fluorine-18 Radiopharmaceuticals
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Fluorine-18 Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ANSTO, Rosatom, Eckert & Ziegler, CNNC, Curium Pharma, GE HealthCare, Jubilant Radiopharma, Cardinal Health, IBA, Sumitomo Heavy Industries, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Fluorine-18 Radiopharmaceuticals market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market Segmentation
    Market segment by Type
    Nucleophilic Labeling
    Electrophilic Labeling
    Market segment by Functional
    Metabolic Tracers
    Receptor-Binding Tracers
    Amino Acid Transporters
    Others
    Market segment by Specific Activity
    High Specific Activity
    Low Specific Activity
    Market segment by Application
    Medical Imaging
    Scientific Research
    Major players covered
    ANSTO
    Rosatom
    Eckert & Ziegler
    CNNC
    Curium Pharma
    GE HealthCare
    Jubilant Radiopharma
    Cardinal Health
    IBA
    Sumitomo Heavy Industries
    Sinotau
    Nueclear Healthcare
    DC Pharma
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Fluorine-18 Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Fluorine-18 Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of Fluorine-18 Radiopharmaceuticals from 2021 to 2026.
    Chapter 3, the Fluorine-18 Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Fluorine-18 Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Fluorine-18 Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Fluorine-18 Radiopharmaceuticals.
    Chapter 14 and 15, to describe Fluorine-18 Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.

    Buy now